Journal article
Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis
Oncogene, Vol.20(22), pp.2836-2843
05/2001
DOI: 10.1038/sj.onc.1204410
PMID: 11420695
Abstract
The role of Bcl-2 in TRAIL-induced apoptosis has been investigated in lymphoid cells. Here we show that the human prostatic carcinoma cell line PC3 was sensitive to TRAIL treatment whereas PC3 overexpressing of Bcl-2 was resistant. TRAIL receptors ligation in PC3 activated caspases -2, -3, -7, -8, and -9, induced Bid processing, dissipation of mitochondrial transmembrane potential (Delta Psi(m)), and cytochrome c release. We have detected caspases -8 and -3 only in the cytosolic fraction of cells, but caspases -2, -7, and -9 were found both in cytosolic and mitochondrial fractions. Bcl-2 overexpression did not affect caspase-8 activation although it did change the processing pattern of caspase-3. At the same time, Bcl-2 overexpression inhibited the activation of mitochondrial localized caspases -2, -7, and -9. Bcl-2 also abrogated TRAIL-induced cytochrome c release and dissipation of Delta Psi(m). These findings suggest that TRAIL-induced apoptosis in the epithelial cell line PC3 depends both on mitochondrial integrity and caspase activation.
Details
- Title: Subtitle
- Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis
- Creators
- Oskar W RokhlinNatalia GusevaAgshin TagiyevC Michael KnudsonMichael B Cohen
- Resource Type
- Journal article
- Publication Details
- Oncogene, Vol.20(22), pp.2836-2843
- DOI
- 10.1038/sj.onc.1204410
- PMID
- 11420695
- NLM abbreviation
- Oncogene
- ISSN
- 0950-9232
- eISSN
- 1476-5594
- Language
- English
- Date published
- 05/2001
- Academic Unit
- Pathology; Radiation Oncology
- Record Identifier
- 9984047695002771
Metrics
24 Record Views